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Overview of Phthalate Ester
Pharmacokinetics in Mammalian Species
by William M. Kluwe*
Phthalic acid esters, or phthalate esters, are generally well absorbed from the gastrointestinal
tract following oral administration. Hydrolysis to the corresponding monoester metabolite, with
release of an alcoholic substituent, largely occurs prior to intestinal absorption of the
longer-chain alkyl derivatives such as di(2-ethylhexyl) phthalate (DEHP). Phthalate esters are
widely distributed in the body, with the liver being the major, initial repository organ. Clearance
from the body is rapid and there is only a slight cumulative potential. Short-chain dialkyl
phthalates, such as dimethyl phthalate, can be excreted in an unchanged form or following
complete hydrolysis to phthalic acid. Longer-chain compounds such as DEHP, however, are
converted principally to polar derivatives of the monoesters by oxidative metabolism prior to
excretion. A marked species difference in DEHP metabolism exists: primates (man, monkey,
some rodent species) glucuronidate DEHP at the carboxylate moiety following hydrolysis of a
single ester linkage, whereas rats appear to be unable to glucuronidate the monoestermetabolite
and oxidize the residual alkyl chain instead to various ketone and carboxylate derivatives. The
major route ofphthalate ester elimination from the body is urinary excretion. Certain phthalate
esters are excreted in the bile but undergo enterohepatic circulation.
The relationships of phthalate ester pharmacokinetics to their toxicological actions are
unknown at the present time, largely due to a lack of elucidated mechanisms of toxic action.
Introduction
It is the intent of this paper to furnish readers
with a general background in phthalate ester phar-
macokinetics, with emphasis on absorption, distri-
bution, metabolism and excretion in several mam-
malian species. Subsequent papers in these pro-
ceedings address the absorption and metabolism of
specific phthalates in more detail than is contained
herein. The greatest amount of data, by far, has
been collected on di(2-ethylhexyl) phthalate (DEHP),
the most commonly used ofthe poly(vinyl chloride)
(PVC) plasticizers. There seem to be sufficient
similarities in some pharmacokinetic parameters of
the compounds studied to date, however, to permit
inferences to be drawn of the pharmacokinetics of
dialkyl phthalate esters in general. Attempts to
correlate similarities inpharnacokineticsto ageneric
pattern of toxicity for dialkyl phthalates await
elucidation ofprobable mechanisms oftoxic action.
*National Toxicology Program, NIEHS, P.O. Box 12233,
Research Triangle Park, North Carolina 27709.
Chemical Structures and
Properties
Structurally, phthalate esters consist of paired
ester groups on a cyclohexatriene ring (benzene-
dicarboxylic acid) (Table 1). The meta and para
configurations are known as isophthalates and tere-
phthalates, respectively. The ortho configuration,
however, is implied in the generic use ofthe term,
"phthalate esters." Phthalate esters are synthe-
sized commercially by condensation of appropriate
alcohols with phthalic anhydride as indicated in
Table 1. The structures of the ester substituents
and the corresponding chemical names of many of
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Table 1. Structures of several common phthalate esters.
0 +
,/
HO-R
HO-R
R R' Compound
- H - H Phthalic acid
- CH3 - CH3 Dimethyl phthalate
- CH2CH(CH2)3CH3 - CH2CH(CH2)3CH3 Di(2-ethylhexyl) phthalate
CH2 CH3 CH2 CH3
- CH2CH20CH3 - CH2CH20CH3 Di(2-methoxyethyl) phthalate
- (CH2)3CH3 - CH2C6H5 Butyl benzyl phthalate
- (CH2)3CH3 - CH2COO(CH2)3CH3 Butylglycolyl butyl phthalate (Butyl phthalylbutyl glycolate)
the more widely used phthalate esters are also
shown. In the related plasticizers, the adipate
esters, a four-carbon chain separates the two ester
groups.
Specific phthalate esters with short alkyl groups,
such as dimethyl and di-n-butyl phthalates, are
appreciably soluble (e.g., 0.5 g/100 ml) in water (1).
Most other dialkyl phthalates, however, including
DEHP, are relatively insoluble in aqueous medi-
ums because oftheir lipophilic structures. Volatili-
ties at standard temperature and pressure are
generally low, particularly for the long-chain and
branched compounds, such as DEHP.
Absorption
Dermal and pulmonary tissues would not be
predicted to be major barriers to absorption of
phthalate esters from the skin or lungs because of
the lipophilic nature ofthe chemicals. Quantitative
(and in most cases qualitative) data on absorption
bytheseroutes, however, arenonexistent orunavail-
able at the present time. Phthalate esters, princi-
pally DEHP, can also be introduced directly into
the circulatory system by the use of plasticized
PVC medical equipment (e.g., syringes or tubing)
or by infusions from plasticized PVC blood bags.
For other than occupationally or medically exposed
populations, however, the most common mode of
human contact with phthalate esters is ingestion
with food or liquids.
The extent of intestinal absorption of phthalate
esters has been estimated by monitoring urinary
excretion of the compounds or their metabolites
after administering a known amount of compound
orally. Shown in Table 2 are the approximate
percentages of the ingested dose extracted from
the urine of rats given one of several phthalate
esters. Absorption ofphthalic acid itselfappears to
be incomplete, but in excess of90% oforal doses of
di-n-butyl phthalate over a range of 60 mg/kg to
2.31 g/kg was excreted in the urine within 2 days,
indicating complete or near-complete intestinal
absorption of this compound. Lesser percentages
(- 40-50%) of DEHP given by gavage in doses
of3 mg/kg or 1.0g/kgappeared inurine, butgreater
than 90% of concentrations of 10 or 2000 ppm
incorporated in feed were excreted by this route
(Table 2). Thus, DEHP in food appears to be very
well absorbed from the intestine over a very wide
concentration range. The data in Table 2 also
indicatethatdi(3,5-dimethoxyethyl)phthalate, butyl
phthalylbutyl glycolate and the DEHP hydrolysis
product, mono(2-ethylhexyl) phthalate (MEHP) are
all well absorbed from the intestine. Based on this
infonnation, itcanbespeculatedthatdialkylphthalate
esters, in general, are well absorbed following oral
ingestion. In contrast, little is known ofthe absorp-
tive characteristics of phthalate esters with aro-
matic alcohol substituents.
Both ester linkages of phthalate esters can be
hydrolyzed, leaving phthalic acid as a product.
Hydrolysis ofa single ester group, however, occurs
much more readily than hydrolysis of the second.
Esterases capable of generating the monoester
metabolite are present in several mammalian tis-
sues (9), including intestinal mucosal cells (10).
Extracellular enzymes present in the intestinal
contents are also capable ofhydrolyzing DEHP and
other phthalate esters (10, 11). As shown in Table
3, short-alkyl-chain congeners are more readily
metabolized by intestinal contents than are long-
alkyl-chain congeners; the extent of completeness
ofthe reaction is also inversely proportional to the
concentrations of the diester compounds.
The hydrolytic activity ofthe intestinal contents
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Table 2. Estimation of intestinal absorption of phthalate esters in rats.
Percentage ofdose
Compounda Doseb Timec excreted in urine Reference
PA 40 mg/kg 4 days 25 (2)
DBP 60 mg/kg 48 hr 90 (3)
270 mg/kg 48 hr 90 (4)
2.31 g/kg 48 hr 90 (5)
DEHP 3 mg/kg 4 days 40 (6)
1 g/kg 24 hr 50 (4)
10 ppmd e > 90 (4)
2000 ppmd e > 90 (4)
MEHP 50 mg/kg 24 hr 70 (7)
DiOP 50 mg/kg 4 days 60 (8)
BPBG 50 mg/kg 4 days 80 (8)
aPA, phthalic acid; DBP, di-n-butyl phthalate; DEHP, di(2-ethylhexyl) phthalate; MEHP, mono (2-ethylhexyl) phthalate; DiOP,
di(3,5-dimethylhexyl) phthalate; BPBG, butyl phthalylbutyl glycolate.
bOral gavage, unless specified otherwise.
'Period of sample collection, between exposure and termination.
dConcentration incorporated into feed.
eTime not reported.
Table 3. Hydrolysis of phthalate esters by rat intestinal contents.a
Compoundb Concentration, mg/ml Portion metabolized, %C Reference
DMP 1 60 (11)
DBP 1 80
DEHP 1 20
DOP 1 10
DEHP 0.1 100 (10)
'The chemicals were incubated for 16 hr at 37°C under an N2 atmosphere in 20% (v/v) suspensions of gut contents in
phosphate-buffered Ringers solution containing 1% (w/v) D-glucose.
bDMP, dimethyl phthalate; DBP, di-n-butyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DOP, di-n-octyl phthalate.
'Percent metabolized in 16 hr.
towards phthalate esters in vitro is heat (boiling)
labile, but unaffected by either filtration ofcellular
material or by bacteriocidal sterilization of the gut
(10, 11). Hence, the hydrolytic activity appears to
be enzymic in nature, though not ofbacterialorigin.
Albro and Thomas (12) have reported very high
hydrolytic activity towards DEHP in pancreatic
homogenates, implicating the intestinal secretion of
pancreatic enzymes as a source of gut hydrolytic
activity towards phthalate esters, and predicting
that little or no intact diestercompound is absorbed
from the intestine. The latter hypothesis, that
primarily MEHP is absorbed after oral administra-
tion of DEHP, raises the question of whether oral
and intravenous (and, possibly, inhalation and der-
mal) routes of DEHP administration represent
similar or dissimilar types of exposure.
Distribution
Some of the earlier studies on phthalate ester
distributions in the body, particularly those using
the intravenous route, were complicated by poor
aqueous solubility of the chemicals and artifacts
later attributed tophthalate-solubilizerinteractions.
Morerecentstudieshaveutilizedplasma-solubilized
compounds. Virtually all DEHP in blood is protein-
bound, approximately 80% to lipoproteins and the
rest to albumin (13). MEHP in blood, ostensibly a
product of DEHP hydrolysis by blood esterases
(14), equilibrates between free and albumin-bound
forms (13).
Whether administered by oral or parenteral
routes, DEHP and di-n-butyl phthalate (DBP), the
two compounds studied most extensively, are rap-
idly cleared from the body (3-6, 15). The bulk ofthe
chemicals is cleared within 24 hr and nearly none is
left 3-5 days after exposure; there is little or no
evidence oftissue accumulation or prolonged tissue
retention. The pharmacokinetic behavior ofMEHP
is similar to that of DEHP (7). Fat, absorptive
organs (gastrointestinal tract) andexcretory organs
(liver, kidney, gastrointestinal tract) are the major
initial repositories for the dialkyl esters (Table 4).
MEHP is not readily deposited in adipose tissue
(Table 4), suggesting that perhaps unmetabolized
dialkyl compounds, rather than their monoester
metabolites, partition most readily into fat. Liver,
kidney and gastrointestinal tract probably accumu-
late the phthalate esters as a mechanism of exere-
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Table 4. Distribution of orally administered phthalate esters.
Compounda Species Dose, mg/kg Time' Repository organs Reference
DBP Rat 60 24 hr Intestine, adipose, liver, kidney, muscle (3)
Rat 270 24 hr Liver, kidney, adipose (5)
48 hr None
DEHP Rat 500 24 hr Intestine, stomach, liver, kidney, adipose (15)
Rat 800 24 hr Liver, kidney, adipose, muscle, testis (4)
4 days Adipose
DiOP Rat, dog, pig 50 4 hr GI, adipose, liver, muscle (8)
24 hr GI, adipose
4 days None
MEHP Rat 69 24 hr Intestine, heart, liver, kidney, lungs, muscle (7)
BPBG Rat, dog, pig 50 4 hr GI, liver, muscle, adipose (8)
24 hr GI
4 days None
aDBP, di-n-butyl phthalate; DEHP, di(2-ethylhexyl) phthalate; DiOP, di(3,5-dimethylhexyl) phthalate; MEHP, mono(2-ethylhexyl)
phthalate, BPBG, butyl phthalylbutyl glycolate.
bTime between administration and examination.
Table 5. Steady-state concentration of DEHP in rat liver and abdominal fat upon prolonged dietary ingestion.a
Dietary conen = 1000 ppm Dietary conen = 5000 ppm
Time, weeks Liver Fat Liver Fat
On diet
1 50 ppm 4 ppm 120 ppm 25 ppm
2 40 ppm 8 ppm 165 p,m 60 ppm
3 46 ppm 7 ppm
4 46 ppm 9 ppm 110 ppm 60 ppm
5 36 ppm 8 ppm 115 ppm 80 ppm
Off diet
1 2 ppm 4 ppm 20 ppm 35 ppm
3 none 3 ppm none 20 ppm
aData derived from Daniel and Bratt (6) with the permission of the authors and Elsevier/North Holland. Calculated from
radioactivity recovered in the tissues after dietary administration of 14C-DEHP.
bNot determined.
tion (e.g., urine, bile) and may, therefore, be
inappropriately labeled as repositories.
Daniel and Bratt (6) examined tissue accumula-
tion ofDEHP in rats by monitoring radioactivity in
fat and liver after dietary exposure to 14C-DEHP.
A synopsis of their results is contained in Table 5.
Steady-state concentrations in liver were achieved
within a week ofinitiation oftreatment, while that
in fat required 2 weeks. The organ difference in
time to achieve a steady-state level was mirrored
by a difference in the rate of decline after removal
of DEHP from the diet: radioactivity in the liver
was reduced by 80% in 1 week, and was below
detection limits within 3 weeks, while radioactivity
in fat was reduced only to approximately one-third
of the steady-state level within 3 weeks (Table 5).
Thesteady-statetissueconcentrations ofradioactiv-
ity were proportional tothe concentration ofDEHP
in the diet, indicating that saturation of tissue
accumulation had not occurred at up to 1000 ppm in
the diet. In contrast to high-dose, oral studies in
rats, significant fractions'of the cumulative dose of
DEHP were reported to be retained for several
months in the livers of rhesus monkeys infused
(intravenously)repeatedly with very smallamounts
(cumulative doses of 21-69 mg/kg) of DEHP in
blood (16).
Surprisingly little is known of the abilities of
phthalate esters to be transferred to offspring.
Radioactivity was recovered from fetal tissues
following treatment of the maternal animals with
14C-DEHP or 14C-diethyl phthalate (17). The con-
centrations in the fetal tissues did not exceed those
in the maternal tissues. Maternal-fetal transfer of
dialkyl phthalate esters across the placenta, there-
fore, is likely. Excretion into maternal milk is also a
distinct probability since lipophilic chemicals read-
ily partition into high fat materials such as breast
milk.
Metabolism
Dialkylphthalatesaremetabolizedtothemonoester
products by enzymes present in many tissues, but
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only those in liver are capable of hydrolyzing
DEHP completely to phthalic acid (12), as shown in
Eq. (1). Appreciable amounts ofdimethyl phthalate
are excreted as phthalic acid, while only very small
fractions of DEHP and other long-chain alkyl
phthalates are converted to this product (18, 19).
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Dimethyl phthalate and, to a lesser extent, DBP
can be excreted in urine as the parent, unchanged
compounds or as their monoester metabolites (18).
Phthalate esters with longer chain lengths, howev-
er, such asDEHP, mustundergofurthermodification
afterhydrolysis tothe monoesterto achieve sufficient
polarity for renal excretion. The data in Table 6
indicate that several species ofanimals form glucu-
ronide conjugates with the monoester metabolite of
DBP at the free carboxylate group. The ferret,
African Green monkey and man form glucuronide
conjugates ofMEHP, as well, but rats appear to be
unable to do so (Table 6). Recent evidence indicates
that hamsters, guinea pigs and mice also excrete
glucuronide conjugates of MEHP (20). The reason
for the inability of rats to conjugate MEHP is
unknown. In addition to glucuronidation, the resid-
ual alkyl chain is oxidized prior to urinary excretion
of the metabolites (3, 21-26).
The inability of the rat to metabolize DEHP
synthetically requires extensive oxidation of the
remaining 2-ethylhexyl moiety to achieve water
solubility. A schematic ofthe metabolism ofDEHP
in rats, as deduced by Albro et al. (19), is shown in
Eq. (2). The same general pathways have been
documented for metabolism ofthe monoester deriv-
atives of other dialkyl phthalate esters (2-7, 18).
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Following initial oxidation of the terminal (w) or
adjacent (w - 1) carbon atom in the side chain to an
alcohol, aldehydes, ketones and carboxylic acids are
formed via successive oxidations. Compounds with
long (six or more linear carbons) alkyl chains may
undergo ,-oxidation and the loss of two-carbon
fragments (18, 19). Generally, the metabolism of
phthalate esters is qualitatively unaffected by the
route of administration (6, 7, 15, 18, 19).
Excretion
The major route ofphthalate ester elimination in
both rodent and primate species, including man, is
urinary excretion (Table 7) (23, 24). Fecal elimina-
tion as a route of excretion has been evaluated for
only a limited number ofphthalate esters (Table 7).
Elimination of di-n-butyl phthalate (DBP) in feces
is nearly nil over a wide dose range. Appreciable
percentages of DEHP appeared in feces when the
compound was given by gavage, but whether the
fecal material represented unabsorbed DEHP or
biliary-exereted material wasnotascertained (Table
7). Similarly, only 4 and 9% of dietary DEHP at
concentrations of 10 and 2000 ppm, respectively,
were recovered from the feces of rats, but it is not
known whether these materials were bile-excreted
or unabsorbed chemical.
Tanaka et al. (3) demonstrated biliary excretion
of DBP to the extent of 44% in 24 hr after an oral
dose of 60 mg/kg. Only 5% of this same dose was
Table 6. Synthetic metabolism of phthalate esters.
Compound Species Route Dose Conjugated metabolites Reference
DEHP Rat PO 500 mg/kg MBP-glucuronide (21) Rat PO 60 mg/kg MBP-glucuronide derivatives (3)
Guinea pig a a MBP-glucuronide derivatives (3)
Hamster a a MBP-glucuronide derivatives (3) DBP Rat Various Various None (4,6,7,15,18,19)
Ferret PO 600 mg/kg MEHP glucuronide derivatives (22)
Monkey IVa MEHP glucuronide derivatives (23)
Human IV 94-171 mg MEHP glucuronide derivatives (24)
aNot reported.Table 7. Biliary, fecal and urinary excretion of DBP or DEHP in rats.
Portion of dose, %b
Compound Dose Timea Route Bile Feces Urine Reference
DBP 60 mg/kg 24 hr PO 44 5 88 (3)
500 mg/kg 6 hr PO 5 -c (21)
2.31 g/kg 48 hr PO 5 82 (5)
50 mg/kg 5 hr IV 10 - (21)
DEHP 2.6 mg/kg 4 days PO 14 56 42 (6)
1.0 g/kg 4 days PO 40 (8) 60 (5)
10 ppm C Feed - 4 (0) 96 (4)
2000 ppm Feed 9 (6) 91 (4)
50 mg/kg 7 days IV 28 49 (15)
aTime of collection post treatment.
bMetabolites in parentheses.
cNot reported.
eliminated in the feces (88% in urine) of nonbile
duct cannulated rats (Table 7), indicating extensive
enterohepatic cycling. As only 5% ofa much larger
dose ofDBP, 500 mg/kg, was recovered from bile in
6 hr (Table 7), hepato-biliary excretion of DBP
metabolites would appear either to be saturated at
high doses or to occur only after a specific period of
time post absorption. The latterpossibility, delayed
biliary excretion, is suggested by the finding that
only 10% of an intravenous dose of 50 mg/kg DBP
was recovered in bile in 5 hr, in comparison to 44%
ofan oral dose of60mg/kgin 24 hr(Table 7). Biliary
metabolites of DBP include monobutyl phthalate,
monobutylphthalateglucuronide and oxidized deriv-
atives of monobutyl phthalate glucuronide (3, 5,
21).
DEHP can also undergo biliary excretion, as
indicated by the report ofDaniel and Bratt (6) that
14% ofan oral dose of2.6mg/kgwasrecovered from
bile. Extraction of28% ofan intravenous dose of50
mg/kg DEHP from feces further indicates that
biliary excretion can be a significant route of
phthalate ester elimination (Table 7). The biliary
metabolites ofDEHP in rats were characterized as
MEHP derivatives; none were glucuronide conju-
gates (6). Although otherstudies did not specifically
collect bile, an estimate of biliary excretion was
obtained by separating fecally eliminated material
into parent compound (presumably unabsorbed)
and metabolites (presumably bile-excreted prod-
ucts). As only 8% ofan oral gavage dose of 1.0 g/kg
DEHP was isolated from feces as DEHP metabo-
lites (Table 7), either biliary excretion is not a
major route of elimination in this dose range or,
more likely, the biliary products are reabsorbed
from the intestine and excreted in urine. Similar
findings occurred in studies where DEHP was
administered with food at concentrations of 10 or
2000 ppm (Table 7). Hence, DEHP metabolites
appear to be excreted in bile to an unknown extent,
reabsorbed from the intestine, and ultimately elim-
inated in the urine.
Relationships of Phthalate
Ester Pharmacokinetics
to Toxic Effects
Speculation on possible relationships between
comparative pharmacokinetics and toxicities are
tenuous, at best, in the absence of well-defined
mechanisms of action. The generally rapid clear-
ance and low potential for tissue accumulation of
the dialkyl phthalate esters, however, is at least
consistent with, if not the cause of, their low toxic
potencies in both acute and chronic studies (25-27).
The primate/rat difference in ability to form glucu-
ronide conjugates of MEHP is suggestive of a
major species difference in chemical metabolism.
Whether or not such a difference renders the rat an
unsuitable model of human response to DEHP
exposure awaits elucidation of the mechanisms of
DEHPtoxicity in rats. However, otherspeciesthat
differ from rats in their ability to glucuronidate
MEHP (e.g., mice) respond with the same types of
toxic injury as do rats (25), indicating possible
independence of chemical toxicity from the ability
of the experimental subjects to form glucuronide
metabolites. Yet to be determined are the precise
mechanisms among several species of oxidation of
the residual alkyl group and whether or not poten-
tial differences in the nature of the oxidation
reaction (e.g., NADH-consuming or NADH-pro-
ducing) could affect the toxic response. In light of
the recent report that DEHP is a hepatocarcinogen
in rats and mice (25), these species differences or
potential differences in DEHP metabolism provide
a strong stimulus for studying the mechanisms of
mammalian response to phthalate ester exposures.
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